Marco Ladetto, Sergio Cortelazzo, Simone Ferrero, Andrea Evangelista, Michael Mian, Rita Tavarozzi, Manuela Zanni, Federica Cavallo, Alice Di Rocco, Vittorio Stefoni, Chiara Pagani, Alessandro Re, Annalisa Chiappella, Monica Balzarotti, Vittorio R Zilioli, Maria Gomes da Silva, Luca Arcaini, Anna L Molinari, Filippo Ballerini, Andrés J M Ferreri, Benedetta Puccini, Fabio Benedetti, Piero M Stefani, Franco Narni, Ivana Casaroli, Caterina Stelitano, Giovannino Ciccone, Umberto Vitolo, Maurizio Martelli
BACKGROUND: Fit patients with mantle cell lymphoma aged 18-65 years are usually given cytarabine and rituximab-based induction regimens followed by autologous haematopoetic stem-cell transplantation (HSCT). We investigated whether post-autologous HSCT maintenance with lenalidomide improves progression-free survival in this population. METHODS: This open-label, randomised, multicentre, phase 3 trial was done at 49 haematology and oncology units in Italy and Portugal...
January 2021: Lancet Haematology